Equities

PharmaCyte Biotech Inc

PMCB:NAQ

PharmaCyte Biotech Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.01
  • Today's Change0.08 / 4.15%
  • Shares traded25.58k
  • 1 Year change-19.28%
  • Beta-0.2491
Data delayed at least 15 minutes, as of Sep 19 2024 20:46 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Apr 30 2024202420232022
ASSETS
Cash And Short Term Investments506885
Total Receivables, Net------
Total Inventory------
Prepaid expenses0.260.110.09
Other current assets, total------
Total current assets506885
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net1.553.553.55
Long term investments01.571.57
Note receivable - long term2.76----
Other long term assets5.160.010.01
Total assets607391
LIABILITIES
Accounts payable0.390.130.21
Accrued expenses0.740.460.50
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total6.30----
Total current liabilities7.420.590.70
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total13----
Total liabilities200.590.70
SHAREHOLDERS EQUITY
Common stock0.000.000.00
Additional paid-in capital185202202
Retained earnings (accumulated deficit)(116)(116)(112)
Treasury stock - common(42)(14)--
Unrealized gain (loss)------
Other equity, total(0.02)(0.02)(0.02)
Total equity407390
Total liabilities & shareholders' equity607391
Total common shares outstanding8.041721
Treasury shares - common primary issue144.810
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.